Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03732534 · ClinicalTrials.gov registry record · Phase 2
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
A Phase 2 study, sponsored by Neurocrine Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03732534: Clinical Trial Phase 2 study, sponsored by Neurocrine Biosciences.
NCT03732534 is a Phase 2 study that was terminated before completion, run by Neurocrine Biosciences. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03732534, a Phase 2 study, was terminated before completion, sponsored by Neurocrine Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide open-label access to NBI-98854 for the treatment of TS for pediatric participants who have taken part in a Phase 2 NBI-98854 study.
Primary Outcome
A TEAE is an adverse event not present prior to the initiation of study drug dosing, or is an already present event that worsens either in intensity or frequency following the initiation of study drug dosing.
Interventions
- DRUG NBI-98854
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-10-17 |
| Est. Completion | 2019-02-18 |
| Phase | Phase 2 |
Why NCT03732534 stopped before completion
NCT03732534 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which NBI-98854 is the first listed.
NCT03732534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03732534 about?
NCT03732534 is a clinical study titled "Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome". This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide open-label access to NBI-98854 ...
What is the current status of trial NCT03732534?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2018-10-17. Estimated completion is 2019-02-18.
What interventions are being tested in trial NCT03732534?
The interventions under investigation include: NBI-98854 (DRUG).
Who is sponsoring clinical trial NCT03732534?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03732534's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI